Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Osteoporosis
Therapy Proven to Consistently Reduce Vertebral Fracture Risk
May 6th, 2000
Procter & Gamble, Cincinnati, Ohio, and Aventis Pharmaceuticals, Parsippany, New Jersey, announced that the U.S. Food and Drug Administration (FDA) approved 5 mg Actonel (risedronate sodium tablets) for the treatment and prevention of postmenopausal osteoporosis (PMO) and glucocorticoid-induced osteoporosis (GIO). Procter & Gamble, the inventor of Actonel, and Aventis Pharmaceuticals will market the drug collaboratively. The approval of Actonel is important to physicians and patients because: Actonel is the first osteoporosis therapy to consistently demonstrate a reduction in vertebral (spinal) fracture incidence in just one year of treatment. New data...
Source: Women's Health Weekly (2000-05-06)
|
